APP and Cognitive impairment: Levetiracetam treatment also reverses synaptic gene changes as well as functional abnormalities and cognitive deficits in APP transgenic mice (Sanchez et al., 2012), whereas decreasing oxidative stress, excitotoxicity and hyperexcitability without interfering with amyloid or tau pathologies prevents AD-related memory deficits (Isopi et al., 2014).